Core Insights - The CSI Hong Kong 300 Biopharmaceutical Index (H300 Biopharmaceuticals) reported a value of 958.77 points, showing a significant upward trend [1] - The index has increased by 2.89% over the past month, 34.24% over the past three months, and 47.43% year-to-date [1] - The index is designed to reflect the overall performance of different industries in the Hong Kong market, based on the CSI industry classification standards [1] Index Composition - The CSI Hong Kong 300 Biopharmaceutical Index consists entirely of securities listed on the Hong Kong Stock Exchange, with a 100% allocation [1] - The index is composed solely of the biopharmaceutical sector, indicating a focused investment strategy [1] Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [2] - Events such as delisting, mergers, or changes in industry classification will prompt corresponding adjustments to the index samples [2]